Asllan Gjinovci worked for 35 years at the Department of Cell Physiology and Metabolism at the University of Geneva, before his employment at University College London in 2012 as senior Research Associate. Since 2017 is seconded at the Francis Crick Institute. Asllan expertise has contributed significantly to the technology of pancreatic perfusion to study drug effects on endocrine and exocrine pancreas secretion. He applied this technology to genetically modified animals and different species and also to other organs such as liver, kidney, gut and spleen. He authored more than 50 high profile research articles as collaborator in global institutions including Laboratory of Molecular Biophysics, Oxford University, (Prof. Robin Offord); Joslin Clinic, Diabetes Center, Medical School, Harvard, (Prof. Gordon Weir) and several others at Universities in Tokyo, Lausanne, Barcelona, Zurich, Pisa, and Basel. He worked as consultant for the California Biotechnology Institute, Montainview; Eli Lilly, Hambourg, F.Hoffmann-La Roche, Basel and the CEED in Strasbourg. During his collaboration with Bonfanti’s group at UCL/Crick he developed the microsurgical approach that has allowed the first whole organ perfusion-decellularisation of the thymus in rodent, pig and human.